AC-003 / Accro Biosci - LARVOL DELTA

Accropeutics Secured $12 Million in Series B Plus Financing (PRNewswire) - "The proceeds from the Series B Plus financing will be used to generate more clinical data for AC-101, a RIPK2 inhibitor, in an ongoing Phase Ib clinical trial for patients with Ulcerative Colitis (UC). Accropeutics' other clinical-stage assets include AC-201, a selective TYK2/JAK1 inhibitor, currently in an ongoing Phase II trial for patients with moderate-to-severe Psoriasis, and for multiple additional indications; and AC-003, a RIPK1 inhibitor, currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage."

Financing • Acute Graft versus Host Disease • Psoriasis • Ulcerative Colitis

Orphan Designation: Treatment of acute graft-versus-host disease (FDA) - Date Designated: 12/11/2023

Orphan drug • Graft versus Host Disease • Immunology